M&A / Deals Regeneron deepens relationship with CytomX, adding up to $2B and eight targets BioSpaceAll told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met.OncologyRead full story pharminent June 4, 2026 (Last updated: June 4, 2026) BioSpace All told, CytomX Therapeutics now stands to receive up to $4 billion over the course of its partnership with Regeneron, if all milestones are met. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Alnylam hops on AI train with up to $2B Inceptive partnershipNext: Peptide biotech Parabilis targets up to $476M IPO Related Stories M&A / Deals Supernus and Indivior merge to create CNS mega-company with 11 approved drugs pharminent August 3, 2026 M&A / Deals J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout pharminent July 31, 2026 M&A / Deals Eisai and CORE Biomedicine agree on global licence for oncology pipeline pharminent July 29, 2026
